PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid

被引：0
|
作者：
Ankit Balhara
Saranjit Singh
机构：
[1] National Institute of Pharmaceutical Education and Research (NIPER),Department of Pharmaceutical Analysis
来源：
Pharmaceutical Research | 2021年 / 38卷
关键词：
DDI; genetic polymorphism; isoniazid; N-acetyl transferase; PBPK modeling;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1485 / 1496
页数：11
相关论文
共 50 条
  • [31] USING PBPK MODELING TO EXPLORE THE IMPACT OF ROUTE OF ADMINISTRATION ON THE METABOLIC DRUG-DRUG INTERACTION (DDI) BETWEEN MIDAZOLAM (MDZ) AND FLUCONAZOLE (FLZ)
    Li, M.
    Venitz, J.
    Li, M.
    Venitz, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S15 - S16
  • [32] Warfarin metabolism and anticoagulant effect:: A prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions
    Muszkat, Mordechai
    Blotnik, Simcha
    Elami, Amir
    Krasilnikov, Irena
    Caraco, Yoseph
    CLINICAL THERAPEUTICS, 2007, 29 (03) : 427 - 437
  • [33] Association of Nat2 Gene Polymorphism with Antitubercular Drug-induced Hepatotoxicity in the Eastern Uttar Pradesh Population
    Yadav, Divya
    Kumar, Rahul
    Dixit, Rakesh K.
    Kant, Surya
    Verma, Ajay
    Srivastava, Kanchan
    Singh, S. K.
    Singh, Sarvesh
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (04)
  • [34] In vitro study of the drug-drug interaction potential of cetagliptin and clinical study of pharmacokinetic interaction of cetagliptin and metformin in healthy volunteers
    Lu, Jinmiao
    Tian, Xusheng
    Tang, Dong
    Zhou, Xinyi
    Xu, Zengyan
    Ding, Juping
    Wang, Tong
    Yu, Qiang
    Ding, Jinsong
    XENOBIOTICA, 2021, 51 (10) : 1122 - 1131
  • [35] Genotype and phenotype of NAT2 and the occurrence of adverse drug reactions in Mexican individuals to an isoniazid-based prophylactic chemotherapy for tuberculosis
    Diaz-Molina, Raul
    Cornejo-Bravo, Jose M.
    Ramos-Ibarra, Marco A.
    Estrada-Guzman, Julia D.
    Morales-Arango, Ofelia
    Reyes-Baez, Ruben
    Robinson-Navarro, Octavio M.
    Soria-Rodriguez, Carmen G.
    MOLECULAR MEDICINE REPORTS, 2008, 1 (06) : 875 - 879
  • [36] Chemogenomics analysis reveals potential molecular mechanism of the drug-drug interaction between statins and fibrates
    Lee, May D.
    Ganter, Brigitte
    Jarnagin, Kurt
    Halbert, Don N.
    FASEB JOURNAL, 2007, 21 (05): : A416 - A416
  • [37] PROSPECTIVE APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING TO INFORM THE DESIGN OF A CLINICAL DRUG-DRUG INTERACTION (DDI) STUDY: CASE STUDY OF MEZIGDOMIDE
    Burnett, J.
    Sychterz, C.
    Zhu, Y.
    Shakeel, F.
    Dingley, K.
    Chen, W.
    Rajadhyaksha, P.
    Shahane, A.
    Wang, X.
    Gaohua, L.
    Lamba, M.
    Gaudy, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S108 - S108
  • [38] Comparative analysis of three drug-drug interaction screening systems against probable clinically relevant drug-drug interactions: a prospective cohort study
    Muhic, Neza
    Mrhar, Ales
    Brvar, Miran
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (07) : 875 - 882
  • [39] Prevalence study on potential drug-drug interaction in piacenza hospital onco-haematology department
    Vecchia, S.
    Confalonieri, C.
    Damonti, E.
    Riva, A.
    Orlandi, E.
    Cavanna, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] Impact of Medication Reconciliation in Oncology Early Phase Studies: A Drug-Drug Interaction Retrospective Study
    Malifarge, Laura
    Deppenweiler, Marine
    Italiano, Antoine
    Lortal, Barbara
    JCO ONCOLOGY PRACTICE, 2024, 20 (03) : 386 - 392
12345